Pharmacotherapies for renal cell carcinoma in Japan.

about

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.Upregulation of long noncoding RNA PVT1 predicts unfavorable prognosis in patients with clear cell renal cell carcinoma.

P2860

Q47564905-8D752545-5E1E-4C7A-8CF0-4D85BE9D3185 Q50224580-142FA0AF-1C85-49BB-9D21-FB5AB8279F2D

P2860

Pharmacotherapies for renal cell carcinoma in Japan.

Item

http://www.wikidata.org/entity/Q38668274

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacotherapies for renal cell carcinoma in Japan.

@en

type

Item

label

Pharmacotherapies for renal cell carcinoma in Japan.

@en

prefLabel

Pharmacotherapies for renal cell carcinoma in Japan.

@en

P1476

Pharmacotherapies for renal cell carcinoma in Japan.

@en

P2093

Hirotsugu Uemura

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Yoshimura

http://www.w3.org/2001/XMLSchema#string

P2860

Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.

Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.

Experience with sunitinib in the treatment of metastatic renal cell carcinoma

Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.

Current status of pharmacotherapy against metastatic renal cell carcinoma in Japan.

Treatment selection in metastatic renal cell carcinoma: expert consensus.

Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.

P304

194-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJU.13008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26663209

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

Pharmacotherapies for renal cell carcinoma in Japan.

about

P2860

P2860

Pharmacotherapies for renal cell carcinoma in Japan.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921